Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma

Annals of Oncology

Volumn 20, Issue 3, 2009, Pages 413-424

  Ruan, J ^a   Hajjar, K ^b   Rafii, S ^b   Leonard, J P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Angiogenesis; Antiangiogenic therapy; Microenvironment; Non Hodgkin's lymphoma; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; BEVACIZUMAB; BLEOMYCIN; BORTEZOMIB; CELECOXIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PANOBINOSTAT; PLATELET DERIVED GROWTH FACTOR; PREDNISONE; PROCARBAZINE; RITUXIMAB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VINCRISTINE SULFATE; VORINOSTAT;

ANGIOGENESIS; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOPENIA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIUM CELL; FATIGUE; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MONOCYTE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERICYTE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOMNOLENCE; T LYMPHOCYTE; THROMBOCYTOPENIA; THROMBOEMBOLISM; UPREGULATION;

ANGIOGENESIS INHIBITORS; HUMANS; LYMPHOMA, NON-HODGKIN; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 61649123322     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn666     Document Type: Review

References (126)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
2. Rafii S, Lyden D, Benezra R et al. Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002; 2: 826-835.
3. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803.
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
5. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-844.
6. Fukumura D, Xavier R, Sugiura T et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998; 94: 715-725.
7. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 1999; 18: 2221-2230.
8. Gerber HP, McMurtrey A, Kowalski J et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30336-30343.
9. Luttun A, Tjwa M, Moons L et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8: 831-840.
10. Hattori K, Heissig B, Wu Y et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 2002; 8: 841-849.
11. Autiero M, Waltenberger J, Communi D et al. Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9: 936-943.
12. Tammela T, Zarkada G, Wallgard E et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454: 656-660.
13. Dias S, Hattori K, Zhu Z et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000; 106: 511-521.
14. Dias S, Hattori K, Heissig B et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001; 98: 10857-10862.
15. Fragoso R, Pereira T, Wu Y et al. VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood 2006; 107: 1608-1616.
16. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007; 13: 680s-684s.
17. Yancopoulos GD, Davis S, Gale NW et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
18. Kieser A, Weich HA, Brandner G et al. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994; 9: 963-969.
19. Hamada K, Sasaki T, Koni PA et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 2005; 19: 2054-2065.
20. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-974.
21. Rak J, Mitsuhashi Y, Bayko L et al. Mutant ras oncogenes upregulate VEGF/ VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575-4580.
22. Dews M, Homayouni A, Yu D et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006; 38: 1060-1065.
23. Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol 2002; 29: 29-37.
24. Mayerhofer M, Valent P, Sperr WR et al. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositol 3-kinase and the mammalian target of rapamycin. Blood 2002; 100: 3767-3775.
25. Manning BD, Cantley LC. AKT/PKB signaling: Navigating downstream. Cell 2007; 129: 1261-1274.
26. Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003; 112: 1142-1151.
27. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125: 1591-1598.
28. Jin DK, Shido K, Kopp HG et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 2006; 12: 557-567.
29. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
30. De Palma M, Venneri MA, Roca C, Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 2003; 9: 789-795.
31. Ruzinova MB, Schoer RA, Gerald W et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 2003; 4: 277-289.
32. Garcia-Barros M, Paris F, Cordon-Cardo C et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155-1159.
33. Duda DG, Cohen KS, Kozin SV et al. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood 2006; 107: 2774-2776.
34. Lyden D, Hattori K, Dias S et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-1201.
35. Peters BA, Diaz LA, Polyak K et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005; 11: 261-262.
36. Grunewald M, Avraham I, Dor Y et al. VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells. Cell 2006; 124: 175-189.
37. Conejo-Garcia JR, Benencia F, Courreges MC et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 2004; 10: 950-958.
38. Yang L, DeBusk LM, Fukuda K et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6: 409-421.
39. De Palma M, Venneri MA, Galli R et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8: 211-226.
40. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-78.
41. Farinha P, Masoudi H, Skinnider BF et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma. Blood 2005; 106: 2169-2174.
42. Rajantie I, Ilmonen M, Alminaite A et al. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 2004; 104: 2084-2086.
43. Darland DC, Massingham LJ, Smith SR et al. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 2003; 264: 275-288.
44. Doussis-Anagnostopoulou IA, Talks KL, Turley H et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol 2002; 197: 677-683.
45. Foss HD, Araujo I, Demel G et al. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol 1997; 183: 44-50.
46. Chen H, Treweeke AT, West DC et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 2000; 96: 3181-3187.
47. Kay NE, Bone ND, Tschumper FIC et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules, Leukemia 2002; 16: 911-919.
48. Koster A, Van Krieken A Mackenzie MA et al. Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res. 2005; 11: 154-161.
49. Jorgensen JM, Sorensen FB, Bendix K et al. Angiogenesis in non-Hodgkin's lymphoma: Clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma 2007; 48: 584-595.
50. Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68-74.
51. Bertolini F, Paolucci M, Peccatori F et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 1999; 106: 504-509.
52. Wang ES, Teruya-Feldstein J, Wu Y et al. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004; 104: 2893-2902.
53. Lee YK, Bone ND, Strege AK et al, VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004; 104: 788-794.
54. Ganjoo KN, An CS, Robertson MJ et al. Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis, Leuk Lymphoma 2006; 47: 998-1005.
55. Gratzinger D, Zhao S, Marinelli RJ et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. Am J Pathol 2007; 170: 1362-1369.
56. Gratzinger D, Zhao S, Tibshirani RJ et al. Prognostic significance of VEGF, VEGF receptors. and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest 2008; 88: 38-47.
57. Stopeck A, Iannone M, Rimsza LM et al. Expression of VEGF, VEGF receptors, and other angiogenic markers in relapsed aggressive non-Hodgkin's lymphoma: Correlative studies from the SWOG S0108 trial. ASH 2004 (Abstr 2288).
58. Ruan J. Coleman M, Furman RR et al, Targeting angiogenesis in mantle cell lymphoma: Clinical efficacy and correlative studies of a phase II trial of RT-PEPC (rituximab, thalidomide and metronomic oral chemotherapy with prednisone, etoposide, procarbazine and cyclophosphamide) in relapsed/refractory disease. Blood 2006; 108: 2751.
59. Potti A, Ganti AK, Kargas S, Koch M. Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma. Anticancer Res 2002; 22: 2899-2901.
60. Ribatti D, Vacca A, Nico B et al. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 1996; 56: 45-53.
61. Ruan J, Hyjek E, Kermani P et al. The magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 5622-5631.
62. Dave SS, Wright G, Tan B et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159-2169.
63. Monti S,. Savage KJ, Kutok JL et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851-1861.
64. Canioni D, Salles G, Mounier N et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELAGOELAMS FL-2000 trial. J Clin Oncol 2008; 26: 440-446.
65. Taskinen M, Karjalainen-Lindsberg ML, Nyman H et al. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007; 13: 5784-5789.
66. Vacca A, Ribatti D, Ruco L et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer 1999; 79: 965-970.
67. Monestiroli S, Mancuso P, Burlini A et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 2001; 61: 4341-4344.
68. Igreja C, Courinha M, Cachaco AS et al. Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients. Haematologica 2007; 92: 469-477.
69. Streubel B, Chott A, Huber D et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004; 351: 250-259.
70. Ferrara N, Keyt B. Vascular endothelial growth factor: Basic biology and clinical implications. EXS 1997; 79: 209-232.
71. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin Oncol 2002; 29: 10-14.
72. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
73. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
74. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
75. Miller KD. E2100: A phase III trial of paclitaxel versus paclitaxel/ bevacizumab for metastatic breast cancer. Clin Breast Cancer 2003; 3: 421-422.
76. Stopeck AT, Bellamy W, Unger J et al. Phase II trial of single agent bevacizumab (Avastin) in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23 (Suppl): 6592.
77. Ganjoo KN, An CS, Robertson MJ et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006; 47: 998-1005.
78. Levine AM, Tulpule A, Quinn DI et al. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: Decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol 2006; 24: 1712-1719.
79. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314-322.
80. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085.
81. Smith SM, Grinblatt D, Johnson JL et al. Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: A phase II trial of the Cancer and Leukemia Group B. Br J Haematol 2008; 140: 313-319.
82. Chanan-Khan A, Miller KC, Takeshita K et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 2005; 106: 3348-3352.
83. Furman RR, Leonard JP, Allen SL et al. Thalidomide alone or in combination with fludarabine are effective treatments for patients with fludarabine-relapsed and refractory CLL. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23 (Suppl): 6640.
84. Kaufmann H, Raderer M, Wohrer S et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004; 104: 2269-2271.
85. Witzig TE, Vose JM, Pietronigro D et al. Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (Suppl): 8066.
86. Wiernik PH, Lossos IS, Tuscano J et al. Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (Suppl): 8052.
87. Czuczman MS, Reeder CB, Polikoff J et al. International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26 (Abstr 8509).
88. Chanan-Khan A, Miller KC, Musial L et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol 2006; 24: 5343-5349.
89. Ferrajoli A, Lee BN, Schlette EJ et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111: 5291-5297.
90. Wang M, Fayad L, Hagemeister F et al. A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (Suppl): 8030.
91. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423-436.
92. Bertolini F, Paul S, Mancuso P et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003; 63: 4342-4346.
93. Shaked Y, Ciarrocchi A, Franco M et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006; 313: 1785-1787.
94. Boyd DB, Coleman M, Papish SW et al. COPBLAM III: Infusional combination chemotherapy for diffuse large-cell lymphoma. J Clin Oncol 1988; 6: 425-433.
95. Coleman M, Gerstein G, Topilow A et al. Advances in chemotherapy for large cell lymphoma. Semin Hematol 1987; 24: 8-20.
96. Coleman M, Leonard JP, Lee C et al. The PEP-C (C3) oral combination chemotherapy regimen for refractory/relapsed lymphoma: Daily prednisone, etoposide, procarbazine and cyclophosphamide. Blood 1999; 94: 94a.
97. Coleman M, Martin P, Ruan J et al. The PEP-C (prednisone, etoposide, procarbazine, and cyclophosphamide) oral combination chemotherapy regimen for relapsing/refractory lymphoma: Low dose metronomic, multidrug therapy. Cancer 2008; 112: 2228-32.
98. Coleman M, Martin P, Ruan J et al. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk Lymphoma 2008; 49: 447-450.
99. Buckstein R, Kerbel RS, Shaked Y et al. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 5190-5198.
100. Bjornsti MA, Houghton PJ. The TOR pathway: A target for cancer therapy. Nat Rev Cancer 2004; 4: 335-348.
101. Witzig TE, Kaufmann SH. Inhibition of the phosphatidylinositol 3-kinase/ mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 2006; 7: 285-294.
102. Mayerhofer M, Valent P, Sperr WR et al. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002; 100: 3767-3775.
103. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135.
104. Witzig TE, Geyer SM, Ghobrial I et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347-5356.
105. Hess G, Romaguera JE, Verhoef G et al. Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice. J Clin Oncol 2008: 26 (Abstr 8513).
106. Smith SM, Pro B, Cisneros A et al. Activity of single agent temsirolimus (CCI779) in non-mantle cell non-Hodgkin lymphoma subtypes. J Clin Oncol 2008; 26 (Abstr 8514).
107. Yee KW, Zeng Z, Konopleva M et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006; 12: 5165-5173.
108. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-5552.
109. Jeong JW, Bae MK, Ahn MY et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002; 111: 709-720.
110. Qian DZ, Kachhap SK, Collis SJ et al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 2006; 66: 8814-8821.
111. Deroanne CF, Bonjean K, Servotte S et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002; 21: 427-436.
112. Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Discov 2007; 6: 21-22.
113. Olsen E, Kim YH, Kuzel T et al. Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutanous T-cell lymphoma (CTCL): Results of a phase IIb trial. J Clin Oncol 2006; 24 (Abstr 7500).
114. Duvic M, Talpur R, Ni X et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31-39.
115. Crump M, Coiffier B, Jacobsen ED et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008; 19: 964-969.
116. Ellis L, Pan Y, Smyth GK et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alteractions in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008; 14: 4500-4510.
117. Crump M, Andreadis D, Assouline S et al. Treatment of relapsed or refractory non-Hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study. J Clin Oncol 2008; 26 (Abstr 8528).
118. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin Cancer Res 2008; 14: 1649-1657.
119. Roccaro AM, Hideshima T, Raje N et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006; 66: 184-191.
120. Shin DH, Chun YS, Lee DS et al. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 2008; 111: 3131-3136.
121. Veschini L, Belloni D, Foglieni C et al. Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. Blood 2007; 109: 2565-2570.
122. O'Connor OA, Wright J, Moskowitz C et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676-684.
123. Goy A, Younes A, McLaughlin P et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667-675.
124. Fisher RI, Bernstein SH, Kahl BS et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867-4874.
125. Belch A, Kouroukis CT, Crump M et al. A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007; 18: 116-121.
126. Buckstein R, Meyer RM, Seymour L et al. Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND. 182-185. Curr Oncol 2007; 14: 154-161.